Calorie restriction triggers the stomach to produce more ghrelin-secreting cells through a specific signaling pathway involving Notch and FOXO1, and tirzepatide mimics part of this effect.
Tirzepatide also expanded ghrelin cellsThe widely prescribed obesity and diabetes drug mimicked part of calorie restriction's effect on stomach hormone cells in mice
What the researchers found
Calorie restriction increased chromogranin A-positive endocrine cells, including ghrelin-producing cells, in mouse stomachs. This expansion was driven by Notch-dependent signaling that activates FOXO1, which promotes a specific subpopulation of endocrine progenitor cells (FOXO1/Neurog3+) to proliferate and differentiate. Blocking Notch with gamma-secretase inhibitors reversed the effect. Uniquely, calorie restriction decreased Lgr5+ stem cells in the stomach (opposite to its effect in the intestine) while increasing endocrine progenitors. FOXO1 activation alone was sufficient to promote endocrine cell differentiation even without Notch signaling. Tirzepatide also expanded ghrelin-producing cells in mice.
Why it matters
This study reveals how calorie restriction — one of the most robust lifespan-extending interventions — reshapes the stomach's hormone-producing machinery at the molecular level. Understanding the Notch-FOXO1 pathway could open doors to drugs that mimic the gut benefits of calorie restriction without actual food restriction. The finding that tirzepatide expands ghrelin cells adds a new dimension to understanding how GLP-1-based metabolic drugs affect the gastrointestinal tract.
How the study worked
Researchers used calorie-restricted mice and examined stomach tissue for endocrine cell changes. They employed primary cell cultures, genetically modified reporter mice (for tracking Lgr5+ stem cells and Neurog3+ progenitors), and pharmacological tools including the Notch inhibitors DAPT and PF-03084014 and the ghrelin receptor antagonist GHRP-6. They also tested tirzepatide administration. Techniques included immunostaining, gene expression analysis, and cell proliferation assays.
What this study cannot tell us
This was entirely a mouse study, and the findings may not translate directly to humans. The abstract does not specify sample sizes for the various experimental groups. The tirzepatide finding is mentioned briefly without detailed dose-response data. The study focused on cell numbers and signaling pathways but did not measure functional outcomes like circulating ghrelin levels or metabolic effects of the expanded ghrelin cell population.
How to read the evidence
This is a preclinical mechanistic study using multiple complementary approaches in mice (in vivo, in vitro, genetic models, pharmacological interventions). The methodology is rigorous for basic science, but findings have not been validated in humans.
When this study was published
Published in 2024 in the Journal of Cell Biology, this is very recent research with high relevance given current clinical interest in GLP-1-based therapies and calorie restriction mimetics.
The bigger picture
Calorie restriction has long been known to extend lifespan in animal models, but its effects on the gut endocrine system have been poorly understood. This work connects calorie restriction to specific stem cell pathways in the stomach and identifies molecular targets that could be pharmacologically manipulated. The tirzepatide finding is particularly intriguing given the massive clinical interest in GLP-1-based drugs, suggesting these medications may have previously unrecognized effects on gastric endocrine cell biology.
Questions still open
- Do patients taking tirzepatide or other GLP-1 agonists show changes in ghrelin-producing cell populations in their stomachs?
- Could targeted activation of the FOXO1 pathway in the stomach replicate the gut benefits of calorie restriction without dietary changes?
- How does the expansion of ghrelin cells during calorie restriction affect overall appetite regulation and metabolic adaptation?
Common questions
Why does the stomach make more ghrelin cells when you eat less?
What does tirzepatide have to do with ghrelin cells?
Read the original research
Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells.
The Journal of cell biology, 223(10)
Citation
McKimpson, Wendy M; Spiegel, Sophia; Mukhanova, Maria; Kraakman, Michael; Du, Wen; Kitamoto, Takumi; Yu, Junjie; Deng, Zhaobin; Pajvani, Utpal; Accili, Domenico. (2024). Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells.. The Journal of cell biology, 223(10). https://doi.org/10.1083/jcb.202305093